Major Cities Business News & Press Release Distribution Services

Major Cities Business News & Press Release services

Unlimited press release distribution service
Business News from U.S Major Cities & Press Release Distribution Services

Bronchodilators Market 2021 Industry Key Trends, Demand and Analysis to 2028

(CityRegions.Com, August 30, 2021 ) Market Overview

Bronchodilators are the medications used for relaxing the muscles by opening the airways or widening the bronchial tubes in the lungs. These medications allow the air to move in and out of the lungs. Bronchodilators are effective in reducing the mucus from the lungs. These drugs are used to treat long-term conditions including asthma, and chronic obstructive pulmonary disease (COPD).

Market Dynamics:

The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others. Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease that causes breathlessness and predisposes to exacerbations and serious illness. According to the World Health Organization (WHO), around 251 million people suffer from Chronic obstructive pulmonary disease (COPD) worldwide. Around 3.17 million people died due to Chronic obstructive pulmonary disease (COPD) worldwide.

The rise in the number of approval of novel bronchodilators shall stimulate market growth. For instance, in November 2018, Theravance Biopharma and Mylan had received approval from the U.S. Food and Drug Administration (FDA) for revefenacin (TD-4208) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Revefenacin would be marketed as an inhalation solution under the brand name Yupelri. Yupelri is a long-acting muscarinic antagonist (LAMA) that acts as a bronchodilator and administrates once daily via a nebulizer.

In April 2019, Circassia had received approval for its medication Duaklir to maintain chronic obstructive pulmonary disease (COPD). Duaklir is a combination of two long-acting bronchodilators, i.e., aclidinium bromide (400 mcg) and formoterol fumarate (12 mcg).

The increase in the research and development activities for the development of bronchodilators. The expected launch of the novel products shall stimulate market growth. For instance, Verona Pharma plc is developing the first-in-class development candidate, i.e., ensifentrine, an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, a bronchodilator and an anti-inflammatory agent in a single compound. However, adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

Segment Analysis

By Drug Type



Phosphodiesterase Inhibitor

Combination Drugs


By Mode of Action

Long-Acting Bronchodilators

Short-Acting Bronchodilators

By Indication

 Asthma

 Chronic obstructive pulmonary disease (COPD)

 Others

By Route of Administration

 Oral

 Injection

 Inhalers

Geographical Presentation

By region, the bronchodilators market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all the regions, North America dominated the bronchodilators market due to the high prevalence of chronic obstructive pulmonary disease (COPD) and Asthma. According to the Centres for Disease Control and Prevention (CDC), around 16 million people suffer from the chronic obstructive pulmonary disease (COPD) in the United States. The prevalence of chronic obstructive pulmonary disease (COPD) increases with rising exposure to air pollutants, genetic factors, and respiratory infections. Around 24 million people had asthma in the United States in 2018. Out of those people, 5 million are children, and 19 million are adults. Asthma is most common among the age-group of 35-64 years. The market is witnessing technological advancement in the development of bronchodilators. The high investment in the research and development activities for bronchodilators shall stimulate market growth.

The Asia Pacific region is expected to have positive market growth due to the increasing number of developing bronchodilators. There is an increase in the availability of bronchodilators. China is expected to have the highest market growth due to a high proportion of the smoking population and tobacco producers. These factors increase the risk of developing the chronic obstructive pulmonary disease (COPD) and Asthma. The growing awareness regarding the use of bronchodilators shall fuel the market growth over the forecasted period.

Competitive Analysis

The bronchodilators market is highly competitive with the presence of several international and local markets. Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc, and Sanofi are the leading market players with significant market share.

Companies are using novel product approvals, new product development, market expansion, and product diversification strategies for holding their position in the market. For instance, in October 2015, Novartis International AG received approval for the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for bronchodilators and their expansion across the globe. For instance, in June 2019, Theravance Biopharma and Mylan had expanded the Yupelri (Revefenacin) development and commercialization agreement to include China and adjacent territories. In February 2015, Theravance Biopharma, Inc entered into the collaboration with Mylan Inc for the development and FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

In September 2014, Akorn, Inc signed a definitive agreement to acquire certain rights to short-acting bronchodilator Xopenex (levalbuterol HCI) Inhalation Solution (IS) Sunovion Pharmaceuticals Inc. for USD 45 million. In September 2012, Sunovion Pharmaceuticals Inc. had acquired Elevation Pharmaceuticals, Inc. (Elevation). The elevation is now a wholly-owned subsidiary of Sunovion and has been renamed Sunovion Respiratory Development Inc. The acquisition included the Elevation's EP-101 product, an inhalation solution long-acting muscarinic antagonist (LAMA) bronchodilator for the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Related Topic's

Cervical Dilator Market, Bronchoscope Market, Intracranial Aneurysm Market, Muscle Stimulator Market, Gastroretentive Drug Delivery System Market

DataM Intelligence

Sai Kiran

+1 877 441 4866

Source: EmailWire.Com


Press release distribution services: Submit press release to major media. Unlimited press release service

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at

CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.

GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | | i-Canada-News.Com | | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | | | | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | - Newswire and Press Release service of GroupWeb Media LLC